Hi Charmaine, according to the study, it lowered T compared to most? I am Hoping Marku might chime in he knows alot about these experimental drugs, this one does seem to have low side effects, but not recomended for the elderly or people with muscle weaknesses

Side EffectsMeta-analysis studies have found significantly increased rates of drowsiness (38% of patients), dry mouth (24%), dizziness (10%), and adverse events of any kind in patients taking cyclobenzaprine versus placebo.[13] Drowsiness and dry mouth appear to intensify with increasing dose.[18]
Other side effects are not significantly more common than they are in patients taking placebo. Some of these include blurred vision, fatigue, nausea, and headache.[18] The sedative effects of cyclobenzaprine are likely due to its antagonistic effect on histamine, serotonin, and muscarinic receptors. Agitation is a common side effect observed especially in the elderly. In general, the NCQA recommends avoiding the use of cyclobenzaprine in the elderly because of the potential for more severe side effects.[19] There is one case report of overdose causing rhabdomyolysis (muscle breakdown).[20]Treatment protocols and support should follow the same as for any structurally-related tricyclic, such as tricyclic antidepressants.[20]

According to the study they stated"12-week period. High-dose cyclobenzaprine resulted in a significant reduction in the Tinnitus"
you can take a cough mixture and it causes drowsiness, it all depends how drowsy this can make a person?

I wonder how significant since they don't really give in THI numbers. It is great to see they are testing all these current drugs and combos for treating T but it seems like it would be hard to get prescribed most of them for T.

Tinnitus, the phantom perception of sounds, is a highly prevalent disorder. Although a wide variety of drugs have been investigated off label for the treatment of tinnitus, there is no approved pharmacotherapy. We report an open-label exploratory pilot study to assess the effect of muscle relaxants acting on the central nervous system on tinnitus patients. Cyclobenzaprine at high (30 mg) and low doses (10 mg), orphenadrine (100 mg), tizanidine (24 mg) and eperisone (50 mg) were administered to a maximum of 20 patients per group over a 12-week period. High-dose cyclobenzaprine resulted in a significant reduction in the Tinnitus Handicap Inventory (THI) score between baseline and week 12 in the intention-to-treat sample. On the other hand, other treatments were not effective. These results were confirmed in an explorative analysis where baseline corrected THI and Clinical Global Impression scores at week 12 were compared between groups. The present open trial presents a new promising pharmacotherapy for tinnitus that should be validated in placebo-controlled double-blind trials.

I have taken flexeril 'on and off' over the last 30 years for back muscle spasms. Initially, flexeril will make most people quite sleepy - but repeated use almost always results in very few negative side effects. (I've had sleep 'triggered' tinnitus for 5 years now - one day I wake up with very bad 'T'- almost debilitating - 2nd day it tends to be 'livable', and by the thirdor 4th day, it usually is incredibly quiet. This 'Cycle' then repeats - but not always as just described). Last year I tried taking flexeril (2, 10mg tabs a couple hrs before bed) on an especially bad day - slept very well, and awoke to total silence. I was elated. I quickly found out it doesn't work by taking it every day. It does, however, seem to work by using it on a very bad day just before bed, almost insuring a very quiet day after.

I tried Cyclobenzaprine (Flexeril) at the low dose of 5mg. It resulted in no significant difference in the pattern of my tinnitus. Of course, the study recommends 30mg at a time. I should note that a friend of mine tried this high dose protocol and did notice some benefits. But like me, he has intermittent tinnitus, and we suspect that the sedating effect was the key to any improvements. I have since taken the odd 5mg dose (when muscles were sore) and awoken to find my tinnitus gone. But again, this is almost certainly because the drug made me really tired.

Of interest is that Flexeril is a close cousin (chemically speaking) to Elavil (Amitripyline): a tricyclic antidepressant that is often prescribed for individuals with tinnitus!

I've seen Flexeril mentioned as a potential treatment of Tonic Tensor Tympani Syndrome (which I have in addition to the tinnitus - but I have not asked for a scrip for it because when I first looked into it I thought I saw something about potential heart problems, etc.

I have a bad neck/back due to Degetive Disc Desease, and stopped taking it Flexeril over a year ago. When I got T this last April, I had a hard time sleeping, so one night I took a flexeril knowing it would help me sleep, and of course it did. I woke the next morning to find my T just about GONE! I had to struggle to try to hear the ringing! I was so excited to have found it works on my T, thinking it would just help me sleep. Yes I wake up feeling out of it but I have found having only two cups of coffee gets me going again. NOTE: That is all the caffeine I have for the day.
I much rather wake up a little sluggish than have the horrible ringing in my head. Hope this helps. Talk to your Doctor about of course.

Thank you so much for this information! What dose do you take? And, if I'm right, you're only taking the Flexeril once a day. And is the the brand name or a generic? I know sometimes generic drugs will not effect the same results.

In 2010, five inventors filed a patent for a sustained-release version of Flexeril for tinnitus. Anyone interested in this drug should read the patent information. According to the inventors, better efficacy is obtainable through a sustained-release formulation of the drug.

Here are some extracts from the patent application, published in 2013:

Treatment of tinnitus and related auditory dysfunctions

ABSTRACT

The invention provides an extended-release dosage form of cyclobenzaprine for use in the treatment of tinnitus and related auditory dysfunctions by once-a-day oral administration, wherein the dosage form is a tablet or capsule comprising cyclobenzaprine as active agent in an amount from 10-80mg, preferably from 10- 60mg. The active agent is associated with a polymer coating or matrix that comprises a water-insoluble polymer, the polymer coating or matrix providing the dosage form with an extended release of the active agent over at least 12 hours and preferably over at least 16 hours when the dosage form is administered to a patient.

...

Cyclobenzaprine is a skeletal muscle relaxant. The exact mechanism of action for cyclobenzaprine is unknown. Current research appears to indicate that cyclobenzaprine acts on the locus coeruleus where it results in increased norepinephrine release, potentially through the gamma fibers which innervate and inhibit the alpha motor neurons in the ventral horn of the spinal cord. Decreased firing of the alpha motor neuron results in decreased muscular tone. Cyclobenzaprine is a muscle relaxant acting primarily on the central nervous system. It is structurally similar to Amitriptyline, differing by only one double bond. Cyclobenzaprine is typically prescribed to relieve pain and muscle spasms. Typically, muscle spasms occur in an injury to stabilize the affected body part and prevent further damage. Whereas this is beneficial in acute injury, muscle spasm frequently persists over time, becomes dysfunctional and can increase the pain level. It is believed that by decreasing muscular spasm, pain is diminished. A common application would be that of a whiplash injury in a car accident. Cyclobenzaprine has also been studied in the treatment of fibromyalgia. In a study of 120 fibromyalgia patients, those receiving Cyclobenzaprine (10 to 40 mg) over a 12 week period had significantly improved quality of sleep and pain score. Interestingly, there was also a reduction in the total number of tender points and muscle tightness. It is also prescribed off-label as a sleeping-aid.

...

As-yet unpublished PCT patent application PCT/IB2010/051373, filed 30 March 2010, relates to cyclobenzaprine for use in the treatment of tinnitus and related auditory dysfunctions by oral administration or by parenteral administration through intramuscular, intravenous, subcutaneous or intrathecal injection or infusion, and presents data demonstrating the efficacy of cyclobenzaprine for these treatments. This unpublished PCT patent application mentions the use of extended release cyclobenzaprine for tinnitus by once-a-day administration but does not provide any details thereupon, neither of the means for providing extended release, nor any other details. Background art on extended-release drug formulations.

...

As shown by the tests reported below, which are taken over from the above- mentioned PCT patent application PCT/IB2010/051373, cyclobenzaprine has a positive effect on tinnitus severity and on tinnitus loudness in the tested subjects, it is safe to administer and though common side effects (like constipation and dry mouth) may be experienced, it is tolerated well by most subjects. Similar results are expected for associated auditory dysfunctions. Generally, according to the invention, the described extended release form of cyclobenzaprine is effective for the treatment of an auditory dysfunction selected from tinnitus, hyperacusis, auditory hallucinations, misophonia, phonophobia and central auditory processing disorders. General aspects of extended-release cyclobenzaprine for treating tinnitus

For many chronic conditions such as chronic pain, management guidelines recommend the use of long-acting, extended-release formulations. Guidelines for pharmacological treatment of tinnitus however have not been established, although tinnitus is a chronic condition. As such, the goal of pharmacological therapy for tinnitus is to provide sustained relief. The use of long-acting, extended-release formulations for tinnitus is desirable because they provide prolonged, more consistent plasma concentrations of drug compared with short-acting agents, thus minimizing fluctuations that could contribute to end-of-dose breakthrough tinnitus. In this regard, a randomized, open-label, two-period crossover, single-centre study, has demonstrated that single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults, provides a controlled release of cyclobenzaprine with sustained plasma concentrations, in contrast to the fluctuating profile of cyclobenzaprine immediate release with comparable systemic exposures.